These findings have established PTP1B as a major target for the treatment of diabetes and obesity and have triggered great efforts from many laboratories to develop specific inhibitors of this enzyme [3]. This evidence concerns the gene PTPN1 and obesity due to melanocortin 4 receptor deficiency.